Ronghua Zhao, MD, PhD.

Chief Medical Officer

Dr. Zhao possesses an in-depth experience of translational medical research and both clinical & non-clinical development of novel anti-cancer drugs. With his strong familiarity with regulations and guidelines of CFDA, FDA, and EMEA, he led the pre-clinical and clinical development of novel oncolytic viruses H101 (Oncorine) and H103, which gained CFDA NDA approval in 2005 – the first oncolytic virus therapy to receive approval worldwide. Additionally, he led the non-clinical development of small-molecule anti-cancer drug candidate, KX02, gaining CFDA IND approval in 2017.

His professional and academic interests continue as he’s declared 3 patents, published 47 papers, and received multiple National Institutes of Health (NIH) and domestic research grants. Dr. Zhao received his PhD Surgery and Bachelor of Clinical Medicine from Second Military Medical University (Shanghai).